-
Mashup Score: 1CAR T-cell therapy brings sustained, drug-free remission in three autoimmune diseases - 2 day(s) ago
Single injections of CD19 chimeric antigen receptor T-cell therapy brought long-lasting remission to 15 patients with three different autoimmune diseases, according to data published in The New England Journal of Medicine.“Although antibody-based B-cell targeting certainly improved treatment of autoimmune disease, achieving long-lasting drug-free remission has proven elusive,” Fabian
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 21Georg Schett - 2 day(s) ago
Find out why Georg Schett is on the TIME100 Health list.
Source: TIME.comCategories: General Medicine News, RheumatologyTweet-
🏆Dr. Georg Schett's pioneering work in CAR-T for #autoimmune disease has landed him among the TIME100 Most Influential People in Health “Not only are the patients in drug-free remission, but I believe many are cured of their autoimmune disease," he said https://t.co/Rj7FpkluNg
-
-
Mashup Score: 0
This symposium is sponsored by the National Institutes of Health (NIH), Office of Research on Women’s Health (ORWH), and the title of this year’s symposium is “Synergy in Science: Innovations in Autoimmune Disease Research and Care.” The symposium will discuss the convergence of cutting-edge…
Source: www.federalregister.govCategories: General Medicine News, RheumatologyTweet-
Read all about it! The 8th Annual Vivian Pinn Symposium is in the Federal Register! Join us on May 15th for an afternoon of science and spectacular #autoimmune stories @NIH_ORWH https://t.co/BFfrkslJUW
-
-
Mashup Score: 7Source of surging autoimmunity may lie in ‘a thousand cuts’ - 1 month(s) ago
The common consensus for some time has been that the prevalence of autoimmunity and autoimmune diseases has been on the rise.Decidedly less common, however, is a widely accepted explanation of why this is occurring.
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
The common consensus is that the prevalence of #autoimmune diseases is rising. But is there any answer why? 🔍In our cover story this month, learn more from Dr. Frederick Miller, Dr. Andrew Wang, Dr. Anca Askanase and @CCalabreseDO 👇 https://t.co/mxayOSIKiZ
-
-
Mashup Score: 1CAR T-cell therapy brings sustained, drug-free remission in three autoimmune diseases - 2 month(s) ago
Single injections of CD19 chimeric antigen receptor T-cell therapy brought long-lasting remission to 15 patients with three different autoimmune diseases, according to data published in The New England Journal of Medicine.“Although antibody-based B-cell targeting certainly improved treatment of autoimmune disease, achieving long-lasting drug-free remission has proven elusive,” Fabian
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💥Single injections of CD19 CAR T-cell therapy brought long-lasting remission to 15 patients with three different #autoimmune diseases, according to new data in @NEJM. Find out more at Healio 🔽 https://t.co/2qBjKtte5h
-
-
Mashup Score: 5
Autoimmune diseases (ADs) are characterized by loss of immune tolerance, high chronicity, with substantial morbidity and mortality, despite conventional immunosuppression (IS) or targeted disease modifying therapies (DMTs), which usually require repeated administration. Recently, novel cellular therapies (CT), including mesenchymal stromal cells (MSC), Chimeric Antigen Receptors T cells (CART) and regulatory T cells (Tregs), have been successfully adopted in ADs. An international expert panel of the European Society for Blood and Marrow Transplantation and the International Society for the Cell and Gene Therapy, reviewed all available evidence, based on the current literature and expert practices, on use of MSC, CART and Tregs, in AD patients with rheumatological, neurological, and gastroenterological indications.
Source: www.thelancet.comCategories: General Medicine News, General HCPsTweet-
Innovative cellular therapies for #autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonisation and guidelines committee https://t.co/hizHbBucIu https://t.co/gVmB71x7Zd
-
-
Mashup Score: 5
Autoimmune diseases (ADs) are characterized by loss of immune tolerance, high chronicity, with substantial morbidity and mortality, despite conventional immunosuppression (IS) or targeted disease modifying therapies (DMTs), which usually require repeated administration. Recently, novel cellular therapies (CT), including mesenchymal stromal cells (MSC), Chimeric Antigen Receptors T cells (CART) and regulatory T cells (Tregs), have been successfully adopted in ADs. An international expert panel of the European Society for Blood and Marrow Transplantation and the International Society for the Cell and Gene Therapy, reviewed all available evidence, based on the current literature and expert practices, on use of MSC, CART and Tregs, in AD patients with rheumatological, neurological, and gastroenterological indications.
Source: www.thelancet.comCategories: General Medicine News, General HCPsTweet-
Innovative cellular therapies for #autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonisation and guidelines committee https://t.co/hizHbBucIu https://t.co/gVmB71x7Zd
-
-
Mashup Score: 6Updates on OADR-ORWH | Office of Research on Women's Health - 4 month(s) ago
Virtual Only
Source: orwh.od.nih.govCategories: General Medicine News, RheumatologyTweet-
Interested in #Autoimmune Disease Research at NIH? Join us for our first OADR-Updates for our community partners at The Office of Autoimmune Disease Research. Register here: https://t.co/KimhkHbefi https://t.co/pB4SWqpYZh
-
-
Mashup Score: 137Human IL-17A protein production is controlled through a PIP5K1α-dependent translational checkpoint - 6 month(s) ago
Nuclear enrichment of the phospholipid PIP2 facilitates interleukin-17 translation by CD4+ helper T cells.
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet-
Scientists delineate how a phospholipid supports the production of an inflammatory molecule that contributes to #autoimmune disease, hinting that this pathway could offer a therapeutic target in conditions such as multiple sclerosis. @SciSignal https://t.co/fQh9Oe1VSa https://t.co/ni6tPneWfV
-
-
Mashup Score: 0FDA grants 510(k) clearance to Werfen’s reagent for connective tissue disease testing - 7 month(s) ago
The FDA has granted 510(k) clearance to Werfen for its Aptiva Connective Tissue Disease Essential reagent to assist in the diagnosis of patients with autoimmune diseases, according to a manufacturer press release.This clearance complements Werfen’s previously cleared Aptiva Celiac Disease IgG reagent, and broadens the offerings of its Aptiva lab system, an automated, high-throughput system
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
📰The FDA has cleared @WerfenNA's newest reagent for #ConnectiveTissueDisease as the company sets its sights on expanding its offerings for other #autoimmune diseases How will this impact patient care? Read more 🔽 https://t.co/cS0MSNFhTr
-
💥Single injections of CD19 CAR T-cell therapy brought long-lasting remission to 15 patients with three different #autoimmune diseases, according to new data in @NEJM. Find out more at Healio 🔽 https://t.co/2qBjKtte5h